Today: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes. It’s an oral, small molecule glucagon-like peptide (GLP)-1 receptor agonist currently in development for the management of type 2 diabetes. Elecoglipron is orally administered once daily with no food or fluid restrictions. This phase 2b study, evaluated the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with type 2 diabetes.
They screened the American participants to be 18 or older with a BMI of 23 kg/m2 (five feet to six-two and between 118 pounds to 180 or higher and all diagnosed with type 2 diabetes.
They needed an A1c between 7·0 and 10·5 managed with diet and exercise alone or monotherapy with metformin or an SGLT2 inhibitor were enrolled.
Participants were randomly assigned to elecoglipron as oral once-daily tablets that would stay the same the entire experiment. They also included three different dose-escalation regimens.
The daily dose of 50 mg was evaluated using an every 2-week dose-escalation schedule. The 75 mg was assessed with every 2-week or every 4-week dose-escalation schedules.
Other participants would act as controls, randomly assigned to placebo matched to each of the elecoglipron groups. Other would take standard oral drugs like Metformin (Glucophage, Glumetza, Riome); Ozempic/Rybelsus, Trulicity, or Victoza; Mounjaro; Jardiance, Farxiga, Invokana; Januvia, Tradjenta, Onglyza; Glipizide, Glimepiride, Diabeta; Actos; or Avandia.
The goal was to change their HbA1c from what they started with. Efficacy, safety, and tolerability were assessed in all participants who received at least one dose of trial treatment.
From Oct 8, 2024, to June 6, 2025, 863 individuals were screened and 406 were enrolled and randomly assigned to one of the eight treatment groups, and 404 participants received at least one dose of trial treatment.
Among those who received at least one dose of trial treatment, on average they were 58·4 years with HbA1c of 7·9%; weight of 220 pounds’; with a BMI 34·9 (mild or low-risk obesity)
Of the 404:
168 were female
236 male
280 (69%) were White
124 (31%) were not White
After 26 weeks
HbA1c fell by .91% and 1·88% compared to the control group which only fell by .15%
Adverse events were reported by 63% to 87% of participants depending on how fast their dosages were increased. (However, even in the control group, 63% reported adverse events.) These events included nausea, constipation, diarrhea, and vomiting.
Interpretation
Once-daily oral elecoglipron showed reductions in glycaemia and a safety and tolerability profile consistent with the GLP-1 receptor agonist class at a similar dosage.
So…there MAY be a new medication to help us deal with Type 2!
To compare with the effectiveness of Metformin, Jardiance, Ozempic, Glucophage, Glucotrol, and Lantis, link here: https://www.nih.gov/news-events/news-releases/two-popular-diabetes-drugs-outperformed-others-large-clinical-trial
LATER, folks!
Article Links: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00802-0/abstract
From the first
moment I discovered I had been diagnosed with DIABETES, I joined a HUGE “club”
that has been rapidly expanding since it stopped being a death sentence in the
early 20th Century. Currently, there are about HALF A BILLION PEOPLE who have
Type 2 Diabetes. For the past 3500 years – dating back to Ancient Egypt –
people have suffered from diabetes. Well, I’m one of them now… Not one to shut
up for any known reason, I added a section to this blog…Every month, I’ll be
highlighting Diabetes research that is going on RIGHT NOW! Harvested from
different websites, journals and podcasts, I’ll translate them into
understandable English and share them with you.
Today: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes. It’s an oral, small molecule glucagon-like peptide (GLP)-1 receptor agonist currently in development for the management of type 2 diabetes. Elecoglipron is orally administered once daily with no food or fluid restrictions. This phase 2b study, evaluated the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with type 2 diabetes.
They screened the American participants to be 18 or older with a BMI of 23 kg/m2 (five feet to six-two and between 118 pounds to 180 or higher and all diagnosed with type 2 diabetes.
They needed an A1c between 7·0 and 10·5 managed with diet and exercise alone or monotherapy with metformin or an SGLT2 inhibitor were enrolled.
Participants were randomly assigned to elecoglipron as oral once-daily tablets that would stay the same the entire experiment. They also included three different dose-escalation regimens.
The daily dose of 50 mg was evaluated using an every 2-week dose-escalation schedule. The 75 mg was assessed with every 2-week or every 4-week dose-escalation schedules.
Other participants would act as controls, randomly assigned to placebo matched to each of the elecoglipron groups. Other would take standard oral drugs like Metformin (Glucophage, Glumetza, Riome); Ozempic/Rybelsus, Trulicity, or Victoza; Mounjaro; Jardiance, Farxiga, Invokana; Januvia, Tradjenta, Onglyza; Glipizide, Glimepiride, Diabeta; Actos; or Avandia.
The goal was to change their HbA1c from what they started with. Efficacy, safety, and tolerability were assessed in all participants who received at least one dose of trial treatment.
From Oct 8, 2024, to June 6, 2025, 863 individuals were screened and 406 were enrolled and randomly assigned to one of the eight treatment groups, and 404 participants received at least one dose of trial treatment.
Among those who received at least one dose of trial treatment, on average they were 58·4 years with HbA1c of 7·9%; weight of 220 pounds’; with a BMI 34·9 (mild or low-risk obesity)
Of the 404:
168 were female
236 male
280 (69%) were White
124 (31%) were not White
After 26 weeks
HbA1c fell by .91% and 1·88% compared to the control group which only fell by .15%
Adverse events were reported by 63% to 87% of participants depending on how fast their dosages were increased. (However, even in the control group, 63% reported adverse events.) These events included nausea, constipation, diarrhea, and vomiting.
Interpretation
Once-daily oral elecoglipron showed reductions in glycaemia and a safety and tolerability profile consistent with the GLP-1 receptor agonist class at a similar dosage.
So…there MAY be a
new medication to help us deal with Type 2!
To compare with the effectiveness of Metformin, Jardiance, Ozempic, Glucophage, Glucotrol, and Lantis, link here: https://www.nih.gov/news-events/news-releases/two-popular-diabetes-drugs-outperformed-others-large-clinical-trial
LATER, folks!
Article Links: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00802-0/abstract Image: https://asploro.com/wp-content/uploads/2019/12/Diabetes-Research_Open-Access.jpg
No comments:
Post a Comment